Etoposide and Teniposide

作者: Malcolm A. Smith

DOI: 10.1007/978-1-59259-307-1_32

关键词: EtoposideMyeloid leukemiaTopoisomeraseLeukemiaTeniposidePharmacologyIn vivoCytotoxicityEpipodophyllotoxinChemistry

摘要: Etoposide and teniposide are epipodophyllotoxins that inhibit topoisomerase II, a ubiquitous enzyme is essential for survival plays critical roles in DNA metabolism, chromosome organization, mitosis (1). act by stabilizing the covalent linkage between II These agents have been studied clinical trials over 25 yr (2, 3), but their contribution to therapy of acute lymphoblastic leukemia (ALL) myeloid (AML) children remains be clearly elucidated. There minor distinctions etoposide teniposide. The latter agent more potent vitro tests cytotoxicity, associated with higher albumin binding, lipophilic, has slightly longer plasma elimination halflife (approx 8 vs 6 h) (4–6). However, these differences do not correlate any therapeutic advantage vivo (7). Randomized studies shown similar levels antitumor activity when used at equitoxic doses (8, 9), current regimens utilize an epipodophyllotoxin employ etoposide. Hence, this chapter, two discussed under assumption they or less interchangeable.

参考文章(84)
W H Meyer, L Kun, N Marina, P Roberson, D Parham, B Rao, B Fletcher, C B Pratt, Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. Journal of Clinical Oncology. ,vol. 10, pp. 1737- 1742 ,(1992) , 10.1200/JCO.1992.10.11.1737
J S Miser, T J Kinsella, T J Triche, M Tsokos, P Jarosinski, R Forquer, R Wesley, I Magrath, Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. Journal of Clinical Oncology. ,vol. 5, pp. 1191- 1198 ,(1987) , 10.1200/JCO.1987.5.8.1191
I Magrath, M Adde, A Shad, D Venzon, N Seibel, J Gootenberg, J Neely, C Arndt, M Nieder, E Jaffe, R A Wittes, I D Horak, Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of Clinical Oncology. ,vol. 14, pp. 925- 934 ,(1996) , 10.1200/JCO.1996.14.3.925
C P Steuber, J Krischer, T Holbrook, B Camitta, V Land, C Sexauer, D Mahoney, H Weinstein, Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. Journal of Clinical Oncology. ,vol. 14, pp. 1521- 1525 ,(1996) , 10.1200/JCO.1996.14.5.1521
N Hakami, A T Look, P C Steuber, J Krischer, R Castleberry, R Harris, Y Ravindranath, T J Vietti, Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: a Pediatric Oncology Group Study. Journal of Clinical Oncology. ,vol. 5, pp. 1022- 1025 ,(1987) , 10.1200/JCO.1987.5.7.1022
S. Joel, K. O’Byrne, R. Penson, D. Papamichael, A. Higgins, H. Robertshaw, R. Rudd, D. Talbot, M. Slevin, A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer Annals of Oncology. ,vol. 9, pp. 1205- 1211 ,(1998) , 10.1023/A:1008437805286
M L Slevin, P I Clark, S P Joel, S Malik, R J Osborne, W M Gregory, D G Lowe, R H Reznek, P F Wrigley, A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. Journal of Clinical Oncology. ,vol. 7, pp. 1333- 1340 ,(1989) , 10.1200/JCO.1989.7.9.1333